23 MAR 1998
REGISTRY OF
TRADE MARKS & PATENTS
SINGAPORE

9703430-0.
IPOS copy

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 9/48, 47/34

A1

(11) International Publication Number: WO 97/07787

(43) International Publication Date: 6 March 1997 (06.03.97)

(21) International Application Number: PCT/US96/12569

(22) International Filing Date: 31 July 1996 (31.07.96)

(30) Priority Data:

08/519,689	25 August 1995 (25.08.95)	US
08/620,021	21 March 1996 (21.03.96)	US
08/622,516	25 March 1996 (25.03.96)	US

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(71) Applicants: SANGSTAT MEDICAL CORPORATION [US/US]; 1505-B Adams Drive, Menlo Park, CA 94025 (US). UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [–/US]; 308 Bynum Hall, Chapel Hill, NC 27599-4105 (US).

(72) Inventors: CHO, Moo, J.; 202 Windhover Drive, Chapel Hill, NC 27514 (US). LEVY, Ralph, E.; 6637 Amber Lane, Pleasanton, CA 94566 (US). POULETTY, Philippe, J.; 3 O'Dell Place, Atherton, CA 94027 (US). FLOC'H, Robert; 9, avenue D'Auray, F-44300 Nantes (FR). MERLE, Christian; 7, impasse Sainte-Radégonde, F-86000 Poitiers (FR).

(74) Agents: ROWLAND, Bertram, I. et al.; Flehr, Hohbach, Test, Albritton & Herbert, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).

(54) Title: ORAL CYCLOSPORIN FORMULATIONS

(57) Abstract

Improved oral cyclosporin formulations which have high bioavailability and are capable of administration in hard capsules or nanoparticles are provided. In the subject formulations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol solvent of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant. The subject formulations may further comprise at least one cosolvent, where cosolvents of interest include fatty acids and diols. The subject formulations find use in immunosuppressive therapy.